PDS Biotechnology (NASDAQ:PDSB) Given New $7.00 Price Target at B. Riley

PDS Biotechnology (NASDAQ:PDSB) had its target price trimmed by B. Riley from $9.00 to $7.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

PDSB has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a report on Friday, November 15th. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. Finally, Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Trading Up 3.8 %

NASDAQ PDSB opened at $2.17 on Monday. The company has a market cap of $81.18 million, a PE ratio of -1.87 and a beta of 1.93. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 12 month low of $1.53 and a 12 month high of $6.68. The stock has a 50 day moving average of $3.10 and a 200-day moving average of $3.19.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the last quarter. Geode Capital Management LLC lifted its holdings in PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after purchasing an additional 37,142 shares during the last quarter. Inspirion Wealth Advisors LLC lifted its holdings in PDS Biotechnology by 1.4% during the 2nd quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after purchasing an additional 4,917 shares during the last quarter. Blair William & Co. IL lifted its holdings in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the last quarter. Finally, XTX Topco Ltd increased its position in PDS Biotechnology by 241.8% during the 3rd quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after buying an additional 47,528 shares during the period. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.